« Return to News | Awards & Advancement

Flint D. Besecker joins Kinex as chief financial officer

Tuesday, July 16, 2013 11:00 AM

Kinex Pharmaceuticals, a specialty biotech focused on the development and commercialization of next generation oral therapies for cancer diseases, has appointed Flint D. Besecker to its executive team as chief financial officer and executive vice president. Besecker will have primary responsibility over all non-scientific aspects of Kinex, reporting to Kinex's chief executive officer, Dr. Johnson Lau. Flint has been an investor and board director of Kinex since 2011.

"Flint has experience in capital markets and strategy having worked for GE Healthcare Financial Services and as founder and president of CIT Healthcare; both fortune 500 companies. He also has experience in a public company environment having led Care Investment Trust's initial public offering and listing on the New York Stock Exchange," Lau said.

Besecker has 20 years of experience in the healthcare industry. He currently runs Firestone Asset Management, a private investment and advisory firm in the healthcare industry. He also is vice chairman of Ameris Acquisitions, a private Nashville hospital company. His previous roles included chief executive officer of the Center for Hospice and Palliative Care, founder of Care Investment Trust, founder of CIT Healthcare, managing director of GE Healthcare Financial Services and chief risk officer of Heller Healthcare.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.